文献速递药物不良反应与药物警戒治疗药物监测与药物基因组学

日本乳腺癌患者多柔比星联合环磷酰胺化疗中性粒细胞减少预测模型的开发

Development of a predictive model for neutropenia risk in Japanese breast cancer patients treated with doxorubicin and cyclophosphamide.
PubMed 文献 · Br J Clin Pharmacol · 2025-08-27

该研究纳入166例接受多柔比星联合环磷酰胺(AC)化疗的乳腺癌患者,按CTCAE v5.0将中性粒细胞减少分为三组,分析严重化疗诱导的中性粒细胞减少(CIN)与生存的关系,并整合33个药代动力学及易感性相关基因多态性构建CIN预测模型。结果显示3-4级无发热性中性粒细胞减少(FN)组10年生存率显著更长,基于7个因素(年龄、血红蛋白、血清肌酐及ABCB1 rs1128503、ERCC1 rs11615、ERCC2 rs238406、XRCC3 rs709399)的4级CIN预测模型AUC为0.744(95%CI 0.666-0.823),加入遗传多态性使预测准确性提高0.128(P=0.004)。

要点

  • 3-4级CIN无FN患者10年生存率96.2%,优于0-2级80.6%和3-4级伴FN 79.0%。
  • 4级CIN预测模型含年龄、血红蛋白、血清肌酐及4个基因多态性,AUC 0.744。
  • 遗传因素加入使模型预测准确性提高0.128(P=0.004)。

核心结论

  • 乳腺癌患者中CIN与生存改善相关。
  • 含遗传因素的预测模型能更准确评估CIN风险,有望支持个体化治疗。

研究设计与样本

  • 研究纳入166例接受多柔比星和环磷酰胺(AC)化疗的乳腺癌患者。
  • 按CTCAE v5.0标准将中性粒细胞减少分为三个严重程度组。
  • 分析严重CIN与生存的关系,并检测33个与药代动力学和易感性相关的基因多态性。
  • 采用多变量逻辑回归整合临床和遗传因素构建CIN预测模型。

主要发现

  • 10年生存率:0-2级组80.6%,3-4级无FN组96.2%,3-4级伴FN组79.0%。
  • 3-4级无FN组生存显著长于其他组。
  • 4级CIN预测模型包含年龄、血红蛋白水平、血清肌酐水平及ABCB1 rs1128503、ERCC1 rs11615、ERCC2 rs238406、XRCC3 rs709399。
  • 模型AUC为0.744(95%CI 0.666-0.823)。
  • 纳入遗传多态性使预测准确性提高0.128(P=0.004)。

临床怎么用

  • 可参考该模型评估接受AC化疗的乳腺癌患者4级CIN风险。
  • 遗传多态性信息有助于提升风险预测准确性,支持个体化给药决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) are important considerations for anticancer drug dosing. Recent studies suggest that CIN may also improve survival. This study aimed to assess the impact of CIN on survival outcomes in breast cancer patients and to develop a predictive model for CIN incorporating genetic factors. METHODS: In 166 breast cancer patients treated with doxorubicin and cyclophosphamide (AC therapy), neutropenia was classified into three severity groups using CTCAE v5.0 criteria. The relationship between severe CIN and survival was analysed. Additionally, 33 genetic polymorphisms linked to pharmacokinetics and susceptibility were examined, and a predictive model for CIN was built using multivariate logistic regression integrating clinical and genetic factors. RESULTS: Among patients receiving AC therapy, the 10-year survival rates were 80.6% for the Grades 0-2 group, 96.2% for the Grades 3-4 group without FN, and 79.0% for the Grades 3-4 group with FN, indicating that patients in the Grades 3-4 group without FN had significantly longer survival. A predictive model for Grade 4 CIN was developed using seven factors: age, haemoglobin levels, serum creatinine levels, and the genetic polymorphisms ABCB1 rs1128503, ERCC1 rs11615, ERCC2 rs238406 and XRCC3 rs709399. The model had an AUC of 0.744 (95% CI, 0.666-0.823), and including genetic polymorphisms improved predictive accuracy by 0.128 (P = 0.004). CONCLUSIONS: CIN was linked to improved survival in breast cancer patients. The predictive model including genetic factors provided a more accurate assessment of CIN risk, potentially enabling more personalized treatment approaches.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Miyagi T, Tsuji D, Nakatani E, et al. Development of a predictive model for neutropenia risk in Japanese breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Clin Pharmacol. 2025. PMID: 40859847. doi:10.1002/bcp.70259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。